Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Emery

Showing results (131-140 of 140) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 140 results.
The Journal of Antimicrobial Chemotherapy|November 27, 2013
An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomesAndrew D Revell, Dechao Wang, Robin Wood, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 29, 2009
High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40)John J Zaunders, Mee Ling Munier, Nabila Seddiki, et al.
Journal of Virology|May 26, 2017
Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment InterruptionWen Shi Lee, Anne B Kristensen, Thomas A Rasmussen, et al.
The New England Journal of Medicine|July 21, 2015
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection, Jens D Lundgren, Abdel G Babiker, et al.
The Lancet. HIV|July 30, 2016
Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trialTorsak Bunupuradah, Sasisopin Kiertiburanakul, Anchalee Avihingsanon, et al.
The Lancet. Respiratory Medicine|October 25, 2016
Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trialKen M Kunisaki, Dennis E Niewoehner, Gary Collins, et al.
The Lancet. HIV|July 21, 2018
Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort studyBenjamin R Bavinton, Angie N Pinto, Nittaya Phanuphak, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 7, 2016
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH StudySarah Lilian Pett, Janaki Amin, Andrejz Horban, et al.
Immunity|November 17, 2021
Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerabilityDeborah L Burnett, Katherine J L Jackson, David B Langley, et al.
NEJM Evidence|May 22, 2023
Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV InfectionJens D Lundgren, Abdel G Babiker, Shweta Sharma, et al.
Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
The Journal of Antimicrobial Chemotherapy|November 27, 2013
An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomesAndrew D Revell, Dechao Wang, Robin Wood, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 29, 2009
High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40)John J Zaunders, Mee Ling Munier, Nabila Seddiki, et al.
Journal of Virology|May 26, 2017
Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment InterruptionWen Shi Lee, Anne B Kristensen, Thomas A Rasmussen, et al.
The New England Journal of Medicine|July 21, 2015
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection, Jens D Lundgren, Abdel G Babiker, et al.
The Lancet. HIV|July 30, 2016
Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trialTorsak Bunupuradah, Sasisopin Kiertiburanakul, Anchalee Avihingsanon, et al.
The Lancet. Respiratory Medicine|October 25, 2016
Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trialKen M Kunisaki, Dennis E Niewoehner, Gary Collins, et al.
The Lancet. HIV|July 21, 2018
Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort studyBenjamin R Bavinton, Angie N Pinto, Nittaya Phanuphak, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 7, 2016
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH StudySarah Lilian Pett, Janaki Amin, Andrejz Horban, et al.
Immunity|November 17, 2021
Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerabilityDeborah L Burnett, Katherine J L Jackson, David B Langley, et al.
NEJM Evidence|May 22, 2023
Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV InfectionJens D Lundgren, Abdel G Babiker, Shweta Sharma, et al.
Pageof 14